Antibiotic research and development in the age of ‘superbugs’

Paul M. Tulkens, MD, PhD
Emeritus Professor of Pharmacology
Invited Professor
(Drug Discovery & Development / Rational) therapeutic choices)

Cellular and Molecular Pharmacology
Louvain Drug Research Institute
Health Science Sector
Université catholique de Louvain
Brussels, Belgium

Disclosures and slides availability

• Research grants
  – Theravance, Astellas, Targanta, Cerexa/Forest, AstraZeneca, Bayer, GSK, Trius, Rib-X, Eumedica
  – Belgian Science Foundation (F.R.S.-FNRS), Ministry of Health (SPF), and Walloon and Brussels Regions

• Speaking fees
  – Bayer, GSK, Sanofi, Johnson & Johnson, OM-Pharma, AstraZeneca

• Decision-making and consultation bodies
  – General Assembly (current) and steering committee (part) of the European Committee for Antibiotic Susceptibility Testing [EUCAST]
  – European Medicines Agency (external expert)
  – US National Institutes of Health (grant reviewing)
  – Belgian Antibiotic Policy Coordination Committee (BAPCOC)

Slides: http://www.facm.ucl.ac.be ➔ Lectures
What shall I talk you about?

• What is the issue / problem we are facing?

• What are the implications?

• Why is this happening?

• Is there really a drying pipeline?

• What needs to be done
Resistance: the current situation

- Bacterial resistance has now reached the point where it has become difficult to be controlled including in several European Countries
  - Witnessed by the yearly surveys from the E-CDC (EARSS network)…
  - Making the choice of antibiotics often hazardous…
  - Causing failures and/or difficult readjustments in situations where early effective therapy is essential …
Two examples of people who should not have died…

Obituary
J.-M. Ghysen

This man discovered the mode of action of penicillin

Dr. Craig was renowned as a clinician-scholar in the fields of antimicrobial therapy and infectious disease. His early work on quantifying the relationship between antimicrobial dosing and treatment effect led to the development of the field of antimicrobial pharmacodynamics.

He died from infectious complications of anticancer therapy

and died from invasive pneumococcal infection … caused by a resistant bacteria
Resistance: the problems we are facing

- Difficulties for the clinician to adjust his/her therapy
  - “Forced use” of combination of antibiotics
    - (increase of the costs and the risk of toxicities)
  - Moving to older, more toxic antibiotics in order to cope with the levels of resistance to current antibiotics
    - (creating new risks)

In some areas, including in Europe, “last resource” antibiotics that would never be registered for large hospital use using the so far “classical” regulatory approval system are now used on a wide scale (e.g., colistin)
Resistance: what are the implications

• increased morbidities (longer treatments…)
• Increased mortalities (failures…)
• Increased costs (more hospitalizations, multiples antibiotics, …)
• Difficulties or even impossibility to use therapies that cause a weakening of the host defenses or to undertake many chirurgical acts…

The clinicians may largely return to pre-antibiotic era and/or will need to resort to other less established therapies (phage, immunotherapies, …)
Resistance: Why is this happening?

Antibiotic therapy will always create resistance …

… but this is accelerated by an inappropriate use

A correct use of antibiotic is essential!

But at the same time, we need to vary the environment to which bacteria are exposed…

- Reviving old but good antibiotics
- Designing new ones

A strong discovery and reassessment pipeline is essential!
But new antibiotics have long been few to reach registration

No new antibiotics: is it true?

- In 2013, an article in *Genetic Engineering & Biotechnology News* identified **66 companies involved in antibiotic research**, 86% of which are either small or medium-sized.

- A paper published in 2013 in *Journal of Antibiotics* (Tokyo)² lists **22 new antibiotics launched since 2000** and discusses the development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of **49 compounds** and **6 β-lactamase/β-lactam combinations** in active clinical development are discussed.

---

1. Genetic Engineering and Biotechnology News 14 Aug 2013
   Last accessed: 8 May 2014
As of December 2014, an estimated 37 new antibiotics¹ that have the potential to treat serious bacterial infections are in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients. This snapshot of the antibiotic pipeline will be updated periodically as products advance or are known to drop out of development.

¹The numbers in the antibiotic pipeline reflect a combination of active compounds, drug candidates, and products in clinical development. This snapshot is based on current information available and may not reflect all products or compounds in clinical development.
So what is the real reason?

The "QALY" of antibiotics

- The quality-adjusted life year (QALY) is a measure of disease burden, including both the quality and the quantity of life lived. It is used in assessing the value for money of a medical intervention.

- If antibiotics prolong your life of 2 to 10 years, and the cost of one year of your life is 20,000 euros, then the value of the "QALY" of an antibiotic treatment is 40,000 to 200,000 euros.

- But the real cost and reimbursement of an antibiotic treatment is MUCH less.

- For comparison, the cost of an anticancer treatment for 1 year survival is up to 20,000 to 70,000 euros… (and the accepted "QALY" is close to that)

- Find where the problem lies…

---

A too simple example from Belgium?

• For **antibiotics** and **antifungals**, if a medical doctor or a dentist prescribes for an **acute treatment**:
  – under the name of the active compound: the rules of prescription under INN (*) are of application (delivery of the cheapest preparation available)
  – under a trade name: as from **1st Mai 2012**, the pharmacist must deliver the product available in the group of « **the cheapest drugs** ».


• The drug acquisition cost for the treatment of a **community acquired pneumonia** following the **recommendations of BAPCOC (**)** (amoxicillin [3 g per day in 3 administrations for 5 to 7 days] is only **13-14 €** … (ex-factory price: ~7 €)


---

* INN: International International Nonproprietary Name
** BAPCOC: Belgian Antibiotic Policy Coordination Committee
A spiral to death (in Belgium) ?

• For antibiotics and antifungals, if a medical doctor or a dentist prescribes for an acute treatment:
  – under the name of the active compound: the rules of prescription under INN (*) are of application (delivery of the cheapest preparation available)
  – under a trade name: as from 1st Mai 2012, the pharmacist must deliver the product available in the group of « the cheapest drugs ».


This infernal spiral (to low prices) make innovators to leave the field

---

For antibiotics and antifungals, if a medical doctor or a dentist prescribes for an acute treatment:
  – under the name of the active compound: the rules of prescription under INN (*) are of application (delivery of the cheapest preparation available)
  – under a trade name: as from 1st Mai 2012, the pharmacist must deliver the product available in the group of « the cheapest drugs ».


The drug acquisition cost for the treatment of a community acquired pneumonia following the recommandations of BAPCOC (**) (amoxicillin [3 g per day in 3 to7 days] is only 13-14 € … (ex-factory price: ~7 €)


---

* INN: International International Nonproprietary Name
** BAPCOC: Belgian Antibiotic Policy Coordination Committee
The market is broken

• The final price of antibiotics is driven to VERY low prices, which makes new antibiotics unprofitable … unless sold widely… **which is NOT what we would like !**

• The EU and the USA have taken useful initiatives to foster the **discovery of new antibiotics**

• But the process of **development and effective and safe availability for the public** still need to be addressed … with **a view on low scale sales**
Trans Atlantic Task Force on Antimicrobial Resistance - TATFAR

2009 EU-US Summit Declaration called for the establishment of “…a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.”

EU-US Summit – Washington 3 November 2009
EU in action … (one example)

THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

- €2 billion euro budget…
- collaborative research projects and networks of industrial and academic experts…
- collaborative ecosystem for pharmaceutical research and development (R&D)…
- increase Europe's competitiveness globally…
- establish Europe as the most attractive place for pharmaceutical R&D

http://www.imi.europa.eu/
Last accessed: 26 May 2015
But additional changes have been brought in the US

- **GAIN Act** (Generating Antibiotics Incentives Now) - 2012
  - priority FDA review
  - additional five years of market exclusivity for breakthrough antibiotics that target serious or life-threatening pathogens
  - relaxed its criterion for non-inferiority to within 10%, making it easier to show comparability to drugs already on the market

- **BARDA**: Biomedical Advanced Research and Development Authority
  [within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services]
  - provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.
We have to reinvent the market in Europe

The European Parliament Resolution of May 19, 2015, on Safer Healthcare in Europe (Improving Patient Safety and Fighting Antimicrobial Resistance) provides some hints:

“62. Calls on the Member States and the Commission to start a reflection process to develop a new economic model, that de-links the volume of sales from the reward paid for a new antibiotic, which would reflect the societal value of a new antibiotic and allow for sufficient return on investment for the company, while the purchaser would gain the right to use the product and have full control over volumes;”

“63e: encourage the development of new revenue models whereby economic returns for companies are de-linked from prescribed volumes of antibiotics, while encouraging pharmaceutical innovation and balancing it with the sustainability of health systems;

The real question is to know who will pay for the de-linking ….

• The Public Authorities (by purchasing the compounds)
• The Industry by obtaining a reasonable price for the efforts made and the low-scale sales